Norway Man Achieves Long-Term HIV Remission After Stem Cell Transplant from Brother

A 63-year-old man in Norway has achieved long-term HIV remission—often described as a functional cure—after receiving a stem cell transplant from his brother. This case marks a significant addition to a small but expanding group of documented patients who have experienced similar outcomes.

Researchers attribute the remission to a combination of rare genetic factors, immune responses, and medication, which appear to eliminate hidden HIV reservoirs. While these cases remain uncommon and are not yet a practical cure for most people living with HIV, they provide critical insights into the complexities of achieving sustained remission.

Understanding HIV and Current Treatment Advances

HIV, or human immunodeficiency virus, is a viral infection that weakens the immune system. Without treatment, it can progress to stage 3 HIV or AIDS (acquired immunodeficiency syndrome). Over the past few decades, advancements in prevention and treatment—such as PrEP (pre-exposure prophylaxis) and antiretroviral therapy (ART)—have dramatically improved outcomes and significantly reduced the risk of HIV transmission.

Despite these breakthroughs, a complete cure for HIV has remained elusive. However, in rare instances, patients have been documented as achieving functional cures following stem cell transplants, including allogeneic hematopoietic stem cell transplantation (HSCT). These transplants are typically performed to treat certain cancers or hematologic disorders unrelated to HIV infection.

Functional cure refers to long-term HIV remission without the need for ongoing antiretroviral treatment. While only a handful of patients have achieved this status, each new case contributes valuable data to the scientific community.

The Oslo Patient: A Case Study in HIV Remission

The patient, now known as the “Oslo patient,” is a 63-year-old man who has been in remission for five years following an HSCT to treat myelodysplastic syndrome. Researchers confirmed his remission by analyzing blood, gut, and bone marrow samples, all of which showed no detectable viral reservoirs.

This case is particularly notable because it represents the first documented instance of HIV remission following a stem cell donation from a sibling. The findings were published in the journal Nature Microbiology.

The Role of the CCR5Δ32 Mutation in HIV Remission

Most documented cases of HIV remission after stem cell transplants have involved donors with the CCR5Δ32 mutation, a rare genetic variation that confers resistance to the most common form of HIV-1, the predominant HIV variant. The CCR5 protein acts as an entry point for HIV to infect immune cells. However, the CCR5Δ32 mutation prevents cells from expressing these receptors, effectively blocking the virus from establishing infection.

The Oslo patient’s brother, who donated the stem cells, carried the CCR5Δ32 mutation. While this mutation appears to play a key role in long-term remission, researchers emphasize that it is not the sole factor contributing to the outcome.

Expert Perspective on the Breakthrough

“There is now a growing consensus that HIV remission is possible, and this case adds to that evidence. It’s a step forward in our understanding of how to achieve sustained control of the virus.”

— Steven Deeks, MD, Professor of Medicine at UCSF, Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General Hospital (not involved in the study)

Deeks’ remarks underscore the significance of the Oslo patient’s case within the broader context of HIV research. While stem cell transplants are not a viable treatment option for most people living with HIV due to their high risk and complexity, each documented case of remission provides valuable clues for future therapeutic strategies.